By Kenneth Rapoza, CPA Industry Analyst A look at how CPA member Nexus Pharmaceuticals defies the drug lobby's claim that medicines made here simply cost...

By Kenneth Rapoza, Industry Analyst, CPA President Trump and many members of Congress are talking about reshoring pharmaceutical production. We look at the benefits of...

By Kenneth Rapoza, CPA Industry Analyst The US needs a "whole-of-government" approach to re-shore production if Americans are ever going to produce what we consume....

By Kenneth Rapoza, Industry Analyst, CPA The latest Chinese company additions to the Commerce Department's Entity List shows the growing influence of national security in...

By Kenneth Rapoza, Industry Analyst, CPA Joe Biden's trade team has the right ideas on China. Here are some standouts we note in his Made...

By Kenneth Rapoza, Industry Analyst, CPA Washing machine prices rose in 2018 and we are all reminded that tariffs are to blame. But they've been...

By Charles Benoit, CPA Trade Counsel A new ruling by U.S. Customs and Border Protection (CBP) will limit the ability of Amazon and other e-commerce...

By Ken Rapoza, CPA Industry Analyst Major pharmaceutical importers have pushed back against the White House's proposal to support domestic labs. But on Thursday, American...

By Kenneth Rapoza The Senate Subcommittee on Security held a hearing on China this week. This is what we learned.

By CPA Staff The Senate takes a stab at reforming the World Trade Organization. But is it even fixable anymore?